Dr. Paul Edmund Sydlowski, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 576 Metacom Ave, Unit 11a, Bristol, RI 02809 Phone: 401-253-4300 Fax: 401-253-0217 |
News Archive
In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "The weekend's newspapers included a pair of headlines about health care reform. And they were probably not the kind that reform advocates like to see" (7/19).
One in 44 (2.3%) 8-year-old children have been identified with autism spectrum disorder according to an analysis of 2018 data published today in CDC's Morbidity and Mortality Weekly Report (MMWR) Surveillance Summaries.
Botox, or botulinum toxin's, main claim to fame currently seems to be associated with stars and others who wish for fuller lips and ironed out wrinkles, but the treatment does in fact have a far more credible and worthwhile reputation which continues to grow.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
Researchers at the Universidad Miguel Hernández and AISOY Robotics are collaborating to expand the potential of their robot assistant for the treatment of children diagnosed with autism spectrum disorder (ASD).
› Verified 2 days ago